当前位置: X-MOL 学术J. Am. Acad. Dermatol. › 论文详情
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Journal of the American Academy of Dermatology ( IF 8.277 ) Pub Date : 2019-12-26 , DOI: 10.1016/j.jaad.2019.12.038
Richard B Warren,Melinda Gooderham,Russel Burge,Baojin Zhu,David Amato,Karen Huayu Liu,David Shrom,Jiaying Guo,Alan Brnabic,Andrew Blauvelt

BACKGROUND Cumulative clinical improvement and speed of improvement are important to psoriasis patients. OBJECTIVE Compare cumulative benefits of biologics over 12 to 16 weeks in the treatment of moderate to severe psoriasis. METHODS A systematic literature review identified phase III trial data on Psoriasis Area and Severity Index (PASI) responses for biologics during 12 and 16 weeks of treatment. Cumulative clinical benefit, measured by the area under the curve for PASI ≥75% improvement (PASI 75), ≥90% improvement (PASI 90), and 100% improvement (PASI 100), was compared using the network meta-analysis and Bayesian methodology on the relative probability of achieving percentage of maximum area under the curve. RESULTS Among biologics approved for psoriasis treatment, anti-interleukin-17 biologics demonstrated consistently greater cumulative clinical benefits on PASI 75, PASI 90, and PASI 100 over the 12- or 16-week period than anti-interleukin-23 and other biologics. For biologics with 12-week data, ixekizumab and brodalumab showed greater cumulative benefits for PASI 75, PASI 90, and PASI 100 than secukinumab, followed by guselkumab, infliximab, adalimumab, ustekinumab, and etanercept. Ixekizumab showed greater cumulative benefits than all other biologics reporting 16-week data. LIMITATIONS Recently approved biologics were not included. CONCLUSION Ixekizumab (at 12 weeks and 16 weeks) and brodalumab (at 12 weeks) had greater cumulative clinical benefit than all of other biologics studied.
更新日期:2019-12-26

 

全部期刊列表>>
物理学研究前沿热点精选期刊推荐
chemistry
自然职位线上招聘会
欢迎报名注册2020量子在线大会
化学领域亟待解决的问题
材料学研究精选新
GIANT
ACS ES&T Engineering
ACS ES&T Water
ACS Publications填问卷
屿渡论文,编辑服务
阿拉丁试剂right
南昌大学
王辉
南方科技大学
彭小水
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
X-MOL
苏州大学
廖矿标
深圳湾
试剂库存
down
wechat
bug